Compressible Polymer Particles for Vascular Embolization

The patent employs parameter changes by adjusting the polymer composition ratios (e.g., PEGDA 2000 at 10-30%, PEGDMA at 5-20%, glycerol monomethacrylate at 50-70%) and molecular weight parameters to achieve the optimal balance between structural stability and compressibility. The crosslinking density and hydrophilic-hydrophobic balance are tuned to enable particles to be rigid enough for stability yet compressible for delivery through catheters with inner diameters of 0.018-0.035 inches.

The patent uses composite materials by combining multiple polymer components with complementary properties: PEGDA 2000 provides structural backbone, PEGDMA adds crosslinking for stability, and glycerol monomethacrylate contributes flexibility and compressibility. This composite approach allows small particles (10-500 μm) to maintain structural integrity despite their size, enabling both easy delivery and stability.

The patent applies universality by designing polymer particles that simultaneously perform multiple functions: mechanical embolization through vascular occlusion and therapeutic drug delivery. The porous structure and hydrophilic polymer composition enable both effective blood flow occlusion and high drug loading capacity for agents like doxorubicin, irinotecan, and paclitaxel, making the particles universally applicable for combined therapy.

The patent employs dynamics by creating particles with adaptive mechanical properties that change under different conditions. The polymer network structure allows particles to be highly compressible during delivery (responding to mechanical compression in catheters) yet maintain structural integrity upon deployment (resisting fragmentation in blood flow). The dynamic balance is achieved through controlled crosslinking density and polymer chain flexibility.